Microfluidics

Portable Microfluidic Biofluid Analyzer Patents Available on the Ocean Tomo Bid-Ask Market® Platform

Retrieved on: 
Friday, April 5, 2024
Breast milk, Dentistry, Microfluidics, Patient, Weight loss, Biomarker, Fertility, Pregnancy, Saliva, Urine, IP, POC, Collection, Auction

CHICAGO, April 5, 2024 /PRNewswire-PRWeb/ -- Ocean Tomo, a part of J.S. Held, announces the auction of a Portable Microfluidic Biofluid Analyzer Patents, available as Lot 187, on the Ocean Tomo Bid-Ask Market® platform.

Key Points: 
  • Held, announces the auction of a Portable Microfluidic Biofluid Analyzer via the Ocean Tomo Bid-Ask Market® platform, supporting patent brokerage, patent auctions and patent transactions.
  • CHICAGO, April 5, 2024 /PRNewswire-PRWeb/ -- Ocean Tomo, a part of J.S.
  • Held, announces the auction of a Portable Microfluidic Biofluid Analyzer Patents, available as Lot 187 , on the Ocean Tomo Bid-Ask Market® platform.
  • To request bidder credentials or to receive further information on this portfolio available on the Ocean Tomo Bid-Ask Market® platform, contact Layna Guo at [email protected] or +1 312 327 8179.

Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits powered by Ultima Genomics sequencing, prototype kits now shipping

Retrieved on: 
Thursday, March 21, 2024
Single-cell analysis, Stem cell, Growth, Cell, WUSTL, Associate, Partnership, Microfluidics, SBIR, Fluency, NIGMS, Genomics, CRISPR, CSO, Fine chemical

This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.

Key Points: 
  • This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.
  • Ultima Genomics sequencing of the prototype million-cell PIPseq data revealed clonal lineage trees with restriction of specific cell reprogramming fates.
  • "The collaboration between Fluent BioSciences and Ultima represents a remarkable synergy in pushing the boundaries of single-cell analysis," said Brian McKernan, CEO of Fluent BioSciences.
  • To learn more about Fluent BioSciences' million-cell PIPseq prototype kits and how they can empower high-throughput single-cell profiling, please contact [email protected] .

World Precision Instruments Partners with TotalLab to Introduce 21 CFR Part 11 into the EVOM Product Line

Retrieved on: 
Wednesday, March 20, 2024
AME Publishing Company, Partnership, Microfluidics, Software, Investment, Drug development, WPI, MPS, Medical device

SARASOTA, Fla., March 20, 2024 /PRNewswire/ -- World Precision Instruments (WPI) is pleased to announce their strategic partnership with TotalLab, paving the way for the integration of 21 CFR Part 11 compliance into its esteemed EVOM family of products.

Key Points: 
  • SARASOTA, Fla., March 20, 2024 /PRNewswire/ -- World Precision Instruments (WPI) is pleased to announce their strategic partnership with TotalLab, paving the way for the integration of 21 CFR Part 11 compliance into its esteemed EVOM family of products.
  • This collaboration marks a significant milestone in WPI's commitment to providing cutting-edge solutions for highly regulated industries, particularly the pharmaceutical market.
  • As part of this partnership, WPI is making substantial investments in both software and hardware capabilities to enhance their product offering.
  • Join WPI at the MPS World Summit and witness how they are revolutionizing precision instrumentation for regulated industries.

Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing

Retrieved on: 
Monday, February 26, 2024
SAN, Hospital, NGD, OEM, Escherichia coli, Infection, NGS, Microfluidics, Life, WGS, Cefepime, Automation, Patient, Economics, Genomics, Standard BioTools, PCR, Laboratory, Partnership, Vaccine

Under the exclusive agreement, Standard BioTools™ will manufacture the NGD-100, a version of its microfluidics-based Biomark™ X9 System customized for NGD and optimized for automated pathogen WGS library preparation.

Key Points: 
  • Under the exclusive agreement, Standard BioTools™ will manufacture the NGD-100, a version of its microfluidics-based Biomark™ X9 System customized for NGD and optimized for automated pathogen WGS library preparation.
  • These systems will enable the cost efficiencies, flexibility and proven analytical performance that laboratories need to meet the increasing demands of pathogen testing.
  • “Standard BioTools’ microfluidics technology represents over 20 years of continuous refinement,” commented Michael Egholm, President and CEO of Standard BioTools.
  • “We have worked closely with NGD to develop this strategic partnership between our companies,” noted Alex Kim, Chief Operating Officer of Standard BioTools.

Microfluidic Devices Patent Monitoring Service 2024: Coverage of the 150 New Patent Families Published Each Month - ResearchAndMarkets.com

Retrieved on: 
Monday, February 19, 2024
Managed Care, Research, Technology, Medical Devices, Hospitals, Health Technology, Science, Engineering, Medical Supplies, Other Technology, Health, Other Science, Manufacturing, Microfluidics, BOSCH, Biotechnology, POC, Chemistry, Invention, Growth, Nanotechnology, HP, IC, Physics, Patent, Microsoft Excel, IP, Q&A, DNA, Biochemistry, Generic drug

In this broad technical area, more than 20,000 patent families related to microfluidics have been published worldwide, and over 150 new patent families are published each month.

Key Points: 
  • In this broad technical area, more than 20,000 patent families related to microfluidics have been published worldwide, and over 150 new patent families are published each month.
  • The microfluidic devices patent monitoring service allows you to take advantage of a monthly updated Excel file and benefit from both quarterly analysis reports and direct interaction with our analysts.
  • This useful Excel patent database allows for multi-criteria searches including priority date, patent assignees, claims, legal status of patents and technology segments.
  • Main patent applicants and their inventions, blocking patents, promising patents and key patents newly expired or abandoned will be highlighted.

SkyWater Signs Production Agreement with Nautilus Biotechnology to Fabricate Novel Biomedical Devices

Retrieved on: 
Thursday, February 15, 2024
Semiconductor, Health, Medical Devices, Technology, Health Technology, Hardware, Biotechnology, ISO, CMOS, SVP, Electronics, Growth, Microfluidics, Commercial, Nautilus, SkyWater Technology, ATS, Medicine, Protein, Plastic, Mobility as a service, Science, Medical device, DNA, Environment, Video game

SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced it has signed a production agreement with Nautilus Biotechnology, Inc. to supply silicon-based microfluidic bio chips for Nautilus’ proteome analysis system.

Key Points: 
  • SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced it has signed a production agreement with Nautilus Biotechnology, Inc. to supply silicon-based microfluidic bio chips for Nautilus’ proteome analysis system.
  • This marks a significant milestone for SkyWater as Nautilus transitions from its Advanced Technology Services (ATS) custom development program to SkyWater’s Wafer Services program.
  • SkyWater is certified to the ISO 13485 Quality Standard for Medical Devices to support the design, development and fabrication of DNA sequencing, lab on chip and other biomedical applications.
  • “We look forward to continuing to support Nautilus as they move toward the commercial availability of their groundbreaking proteome analysis platform.

Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024

Retrieved on: 
Monday, February 5, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Professional Services, Other Science, Research, Medical Devices, General Health, Data Analytics, Health Technology, Science, Data Management, Multimedia, Microfluidics, Kinetics, Fraunhofer Society, BRKR, SPR, Cell therapy, Surface plasmon resonance, Thermodynamics, Bruker, Drug, Drug discovery, Exhibition, Immunology, API, Acquisition, Automation, Software, Conference

At the SLAS2024 International Conference and Exhibition , Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.

Key Points: 
  • At the SLAS2024 International Conference and Exhibition , Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.
  • The SPR #64 system has been engineered from the bottom up to accelerate drug discovery with increased SPR throughput, leading sensitivity and data quality.
  • View the full release here: https://www.businesswire.com/news/home/20240205314598/en/
    ‘Triceratops’ SPR #64: the all new, high-throughput multiplexing Surface Plasmon Resonance (SPR) system (Photo: Business Wire)
    The ‘Triceratops’ SPR #64 system combines highest sensitivity detection with a novel microfluidics concept, which via the perpendicular rotation of the 8-channel flow cell, now facilitates the simultaneous reading of 64 sensor spots.
  • With the ‘Triceratops’ SPR #64, Bruker is now offering drug discovery customers the highest throughput in the industry with uncompromising data quality.

Biosensors and Nanosensors Propel Towards a $43.5 Billion Global Market by 2028 - BCC Research Analysis Unveiled

Retrieved on: 
Wednesday, January 31, 2024
Wearable, Nanotechnology, Microfluidics, Growth, Internet of things, Research, Nanoparticle, Miniaturization, International finance, Nanosensor, Nano, Environmental monitoring, Integration, Sensor, Biosensor, Nanocomposite, Heart rate, Algorithm, BCC, Artificial intelligence, Geography, Health, Market, Medical imaging

BOSTON, Jan. 31, 2024 /PRNewswire/ -- Biosensors and nanosensors represent cutting-edge technologies that have significantly advanced the landscape of global markets. Biosensors are analytical devices that combine biological components with sensors to detect and quantify specific substances, offering applications in healthcare, environmental monitoring, and more. Nanosensors, operating at the nanoscale, leverage nanotechnology to enhance precision and sensitivity in detecting various analytes. The global market for these technologies is characterized by rapid advancements, fueled by innovations in nanotechnology, IoT integration, and miniaturization. These sensors find extensive application in healthcare diagnostics, environmental monitoring, and various industries. This report delves into the dynamic market trends and technologies shaping the biosensors and nanosensors arena, providing valuable insights into the transformative potential of these innovations on a global scale.

Key Points: 
  • The global market for these technologies is characterized by rapid advancements, fueled by innovations in nanotechnology, IoT integration, and miniaturization.
  • "According to the latest BCC Research study, the demand for Biosensors and Nanosensors: Global Markets and Technologies is estimated to increase from $30.6.0 billion in 2023 to reach $43.5 billion by 2028, at a compound annual growth rate (CAGR) of 7.3% from 2023 through 2028."
  • This comprehensive report delves into the intricate details of the worldwide biosensors and nanosensors market, providing a meticulous analysis categorized by product type, technology, application, and geography.
  • The narrative elucidates the primary drivers propelling the global biosensors and nanosensors market, coupled with regional dynamics and prevailing industry trends.

MGI Unveils Comprehensive Expansion of Automation Product Lines for Life Science and Healthcare Research

Retrieved on: 
Tuesday, January 30, 2024
Transfer, Research, COVID, Complete Genomics, Medicine, Genomics, Laboratory, Microfluidics, PCR, Automation, MGI, Microbiology, Fine chemical

SHENZHEN, China, Jan. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. (referred to as MGI), a leading provider of cutting-edge tools and technology for life science and healthcare research, today announced a strategic expansion of its automation product lines. This expansion covers sample pretreatment, sample preparation and integrated testing, leveraging its innovative technologies and expertise in genetic sequencing and multi-omics.

Key Points: 
  • SHENZHEN, China, Jan. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. (referred to as MGI), a leading provider of cutting-edge tools and technology for life science and healthcare research, today announced a strategic expansion of its automation product lines.
  • MGI's automation product lines aim to address the growing demand for high-throughput, efficient and reliable solutions in precision medicine, precision agriculture, precision healthcare and related industries.
  • MGI's expansion of automation product lines emphasizes its commitment to intelligent innovation in life sciences, and providing advanced tools that enhance efficiency, accuracy, and research turnaround times.
  • "MGI is proud to announce the expansion of our automation product lines, providing advanced solutions to our life science and healthcare partners.

Stämm: Pioneering Biomanufacturing Innovator Opens Its European R&D Facility at The BioArk in Monthey, Switzerland.

Retrieved on: 
Friday, January 26, 2024
Employment, Heart, Promotion, Ecosystem, Environment, Microfluidics

MONTHEY, Switzerland, Jan. 26, 2024 /PRNewswire-PRWeb/ -- Stämm, an innovative leader in bioprocessing technology, has announced the opening of its new R&D facility at the BioArk in Monthey, in the canton of Valais. Founded in 2016 in Argentina, Stämm, now boasting a robust team of over 200 in Buenos Aires and San Francisco, specializes in harnessing nature-inspired, data-driven solutions to revolutionize bioprocessing.

Key Points: 
  • With the establishment of its new R&D facility in Western Switzerland, Stämm is set to bring its pioneering technology to the heart of Europe's thriving biotech sector.
  • The new facility at the BioArk in Monthey represents a significant step in the company's global expansion strategy, underscoring its commitment to innovative biomanufacturing processes.
  • Establishing our presence at BioArk in Monthey aligns perfectly with our mission," says Cabaleiro.
  • "Our goal is to solidify our presence and play a pivotal role in Swiss innovation, utilizing our strategic position to expand across Europe," Cabaleiro concludes.